Levels of thrombin-activatable fibrinolysis inhibitor and platelet-activating factor in recurrent pregnancy loss patients.

OBJECTIVE: The aim of this study was to investigate factors associated with thrombosis that may contribute to recurrent pregnancy loss (habitual abortion), specifically differences in serum levels of platelet-activating factor and thrombin-activatable fibrinolysis inhibitor (carboxypeptidase B2) between women with a history of recurrent miscarriage and those with no recurrent miscarriage history. MATERIALS AND METHODS: A case-controlled, prospective study design was adopted to compare women with a history of two or more first-trimester miscarriages (n = 42) with those with no history of recurrent miscarriage (n = 36). Participants were recruited from the Department of Obstetrics and Gynecology of Turgut Ozal University Hospital. Platelet-activating factor and thrombin-activatable fibrinolysis inhibitor levels in serum samples were measured by an enzyme-linked immunosorbent assay. RESULTS: Platelet-activating factor levels were significantly (p = 0.018) higher in the recurrent miscarriage group. There was no difference in levels of thrombin-activatable fibrinolysis inhibitor expression between the groups. CONCLUSION: Platelet-activating factor is significantly higher in serum of patients with a history of recurrent miscarriage than in those without such a history, with potential implications for placental function and fetal growth, which could be relevant to miscarriage recurrence. Larger studies are indicated to further examine these findings.

Endothelin-1 and Nitric Oxide Levels in Exudative Age-Related Macular Degeneration.

PURPOSE: To evaluate plasma levels of endothelin-1 (ET-1) and nitric oxide (NO) in patients with exudative age-related macular degeneration (AMD). METHODS: In this study, ET-1 levels, as well as nitrite plus nitrate concentrations as an indicator of plasma NO level, were measured in the plasma of 20 subjects with exudative AMD and compared with 20 healthy age and sex matched controls. RESULTS: Mean plasma ET-1 level was significantly higher in exudative AMD patients as compared to control subjects (0.35 ± 0.06 fmol/ml versus 0.17 ± 0.03 fmol/ml, P = 0.015). Patients with exudative AMD also showed significantly lower mean plasma levels of nitrite plus nitrate as compared to the controls (58.9 ± 2.7 µmol/l versus 82.6 ± 5.9 µmol/l, P = 0.001). CONCLUSION: Increased concentrations of ET-1 and reduced levels of NO in the plasma may suggest an imbalance between vasoconstrictor and vasodilator agents, respectively, as a reflection of endothelial dysfunction in the pathogenesis of AMD. These findings may also imply the role of vasoconstriction in exudative AMD.

The Effects of Valsartan and Amlodipine on the Levels of Irisin, Adropin, and Perilipin.

BACKGROUND: Hypertension and obesity are two major threats for public health. Up to the present, antihypertensive medications have been used to lower blood pressure, which seem to provide a better life with lower morbidity and mortality rates. Their effect on etiopathogenesis of hypertension is now an area of developing research. The association between hypertension and obesity also suggests the link between antihypertensive agents and energy hemostasis. We aimed to investigate the effects of antihypertensive treatment on the irisin, adropin, and perilipin levels in patients with essential hypertension and to compare them with healthy volunteers in terms of their effect on energy hemostasis. METHODS: In total, 85 newly diagnosed patients with untreated essential hypertension were admitted to the outpatient clinic. Patients were randomized to one of the following treatment protocols: amlodipine or valsartan for a 12 week period. 42 patients were randomized into the valsartan group and 43 patients into the amlodipine group. Serum perilipin, irisin, and adropin levels were measured before and after drug treatment by ELISA kits. RESULTS: We discovered that the hypertensive patients have lower levels of perilipin and higher levels of adropin compared with the control group. Both amlodipine and valsartan increased the levels of perilipin, irisin, and adropin after 12 weeks of treatment. CONCLUSIONS: In conclusion, in regulating energy balance, perilipin, irisin, and adropin, could be of pathogenic importance in obesity-induced hypertension. Hence, ongoing trials need to elucidate this mechanism.

Influence of CPAP treatment on airway and systemic inflammation in OSAS patients.

AIM: Obstructive sleep apnea syndrome (OSAS) is characterized by recurrent respiratory disorders in the upper airways during sleep. Although continuous positive airway pressure (CPAP) has been accepted to be the most effective treatment for OSAS, its role on inflammation remains debatable. In this study, our aim was to examine the influence of 3 months of CPAP treatment on tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), 8-isoprostane, and peroxynitrite levels in exhaled breathing condensates (EBC) and serum. METHODS: Thirty-five patients who were newly diagnosed as moderate or severe OSAS with full night polysomnography and used CPAP therapy regularly for 3 months were included in the study. Polysomnography, spirometric tests, fasting blood samples, and EBC were ascertained on entry into the study and after 3 months of treatment. All patients were assessed monthly for treatment adherence and side effects. RESULTS: We found that all polysomnographic parameters were normalized after CPAP therapy in the control polysomnogram. Also, all markers in EBC and nitrotyrosine and 8-isoprostane levels in serum were decreased significantly with CPAP treatment. Sedimentation rate, C-reactive protein, IL-6, and TNF-α remained unchanged in serum after treatment. We found that baseline nitrotyrosine levels were significantly correlated with apnea-hypopnea index, oxygen desaturation index, and percent time in SpO2 < 90 % (p < 0.01). CONCLUSIONS: CPAP therapy has primarily a relevant impact on airways, and nitrotyrosine levels correlated well with severity of OSAS. This treatment decreases both inflammation and oxidative stress levels in airways in OSAS patients. Also, this treatment helps to decrease systemic oxidative stress levels in serum.

Investigation of trace elements in pterygium tissue.

PURPOSE: In this study, we compare the concentrations of the essential trace elements chromium (Cr), copper (Cu), selenium (Se), manganese (Mn), boron (B) and zinc (Zn) in both pterygium and normal conjunctiva and investigate the role they play in the development of pterygium. METHODS: Included in the study were 38 patients with pterygium and 38 control patients in matching age groups who had been operated on for strabismus or cataracts and in whom conjunctiva samples were collected from the nasal limbus area. All conjunctiva samples were kept at -80 °C until the performance of the biochemical investigations. The B, Cr, Mn, Cu, Zn and Se levels in the samples were then measured. The levels of all tissue trace elements were determined by using Agilent 7500a Inductively Coupled Plasma-Mass Spectrometer (Agilent Technologies, Santa Clara, CA). RESULTS: Cr, Mn, Zn and Se levels are significantly lower in the study group as compared to those of the control group (p < 0.001 for all four values). Regarding the level of B, there was no significant difference between the groups. The Cu levels of almost all subjects in the control group and all subjects in the pterygium group were under the detection limit. CONCLUSIONS: These findings indicate that remarkable differences in Mn, Zn, Se and Cr levels exist in pterygium tissues. Further investigation of electrolyte composition of the conjunctiva is needed to understand the genesis and developmental mechanism of pterygium.

Dose-dependent protective effect of L-carnitine on oxidative stress in the livers of hyperthyroid rats.

OBJECTIVE: The present study was designed to investigate the dose-dependent protective effect of L-carnitine (LC) on thyroid hormone-induced oxidative stress in rat liver tissue. MATERIALS AND METHODS: Twenty-one male Sprague Dawley rats were divided into four groups: control, hyperthyroidism, hyperthyroidism plus L-carnitine 100, and hyperthyroidism plus L-carnitine 500. Hyperthyroidism was induced in rats by injecting 250 µg of L-thyroxine/kg body weight/day for twenty consecutive days. The activities of catalase (CAT), glutathione peroxidase (GPX) and myeloperoxidase (MPO) and the level of malondialdehyde (MDA) were measured in liver homogenates. RESULTS: The liver CAT, GPX and MPO activities were significantly lower in the hyperthyroid rats than in the control group. Treating hyperthyroid rats with both low-dose (100 mg/kg) and high-dose (500 mg/kg) L-carnitine for 10 days resulted in a marked increase in the activities of the antioxidant enzymes in the liver tissue. CONCLUSION: The present study indicates that the low-dose L-carnitine application was sufficient to prevent L-thyroxine-induced oxidative stress in rat livers.

Serum thrombopoietin levels in patients with non-alcoholic fatty liver disease.

OBJECTIVE: To observe thrombopoietin (TPO) levels in patients with non-alcoholic fatty liver disease (NAFLD). METHODS: The study was performed between November 2010 and March 2011 at the Department of Internal Medicine, Faculty of Medicine, Fatih University, Ankara, Turkey. A total of 60 consecutive patients with ultrasound proven NAFLD (study group), and 28 healthy volunteers (control study) were included in the study. The patient group was divided into 3 subgroups according to the ultrasonographic images as follows: minimal, intermediate, and marked hepatosteatosis. The TPO levels of the patient subgroups were compared with the healthy controls. All the data were collected prospectively, and recorded in FUHIS data collecting system, which is produced by our data-knowledge team. Quantitative measurements of thrombopoietin level were carried out by using the Human Thrombopoietin Quantikine ELISA Kit (R&D Systems, Minneapolis, Minnesota, USA). RESULTS: Thrombopoietin levels were significantly increased in the patient subgroups compared with the controls. The TPO levels were also higher in the patient subgroup of grade 1-nonalcoholic fatty liver disease (grade 1- NAFLD) compared with the control group. CONCLUSION: The TPO increased in patients with NAFLD possibly as an acute phase reactant to decreased inflammation. In clinical practice, physicians should be alerted to increased TPO levels in patients.

Influence of obstructive sleep apnea on fatty liver disease: role of chronic intermittent hypoxia.

BACKGROUND: Currently the common pathogenetic mechanisms in nonalcoholic fatty liver disease (NAFLD) and obstructive sleep apnea (OSA) are gaining increased attention. The aim of this study is to find out the influence of chronic intermittent hypoxemia and OSA related parameters to the severity of NAFLD. METHODS: We examined the liver functions tests and ultrasonographic data of liver as well as markers of OSA severity (apnea-hypopnea index [AHI], oxygen desaturation index, minimum oxygen saturation, percentage of time spent with S(pO(2)) < 90%) of 106 subjects. RESULTS: Fatty liver disease was diagnosed in 71 subjects (group 1), and the remaining 35 subjects were taken as controls (group 2). The prevalence of OSA was 71.2% versus 35.7% for group 1 and 2, respectively (P < .001). As NAFLD severity increased from mild to severe form, mean AHI and oxygen desaturation index values also increased significantly. Our multivariate analysis showed that AHI, oxygen desaturation index, lowest desaturation values, and percentage of sleep duration with S(pO(2)) < 90% were independent predictors of NAFLD after adjustment for BMI, weight, and insulin resistance. Furthermore, the most correlated parameter for the severity of NAFLD was found as the duration of hypoxia during sleep. CONCLUSIONS: The prevalence of NAFLD was higher in patients with severe OSA, suggesting a role for nocturnal hypoxemia in the pathogenesis of fatty liver disease.

Effects of the aged garlic extract on spinal cord injury model in rat.

BACKGROUND: Aged garlic extract (AGE) is a potent antioxidant agent with an established neuroprotective effect in cerebral ischemia. However, the potential protective effect of AGE in spinal cord injury (SCI) is still unknown. METHODS: Spinal cord trauma was applied to 19 adult male Wistar rats using the clip compression method. Animals were divided into three groups. Animals in the AGE group were administered 250 mg/kg per day of AGE diluted in tap water orally by gavage for 15 days prior to trauma. After spinal cord trauma, malondialdehyde (MDA) and superoxide dismutase (SOD) levels of the AGE group were compared with the animals in the control and SCI groups. The animals were examined by inclined plane 24 hours (h) after the trauma. At the end of the experiment, spinal cord tissue samples were harvested for pathological evaluation. RESULTS: Regarding tissue MDA and SOD levels after trauma, animals in the AGE group demonstrated decreased MDA levels and increased SOD levels when compared with the SCI group. However, these results were no better than in the control group. The AGE group demonstrated better pathological findings than the SCI group. The result regarding the functional finding was similar. CONCLUSION: AGE demonstrated neuroprotective effects in SCI. Further studies with different experimental settings are required to achieve conclusive results.

Prevention of selenite-induced cataractogenesis by N-acetylcysteine in rats.

PURPOSE: To evaluate the effect of N-acetylcysteine on selenite-induced cataract formation in a rat model. MATERIALS AND METHODS: Thirty-four Sprague-Dawley rat pups were divided into three groups. Eight pups received only selenite on postpartum day 10 (group 1), 14 pups received selenite on day 10 and additional acetylcysteine on postnatal days 9 to 15 (group 2), and 12 pups received only saline (group 3, control). All pups were daily examined for the presence of cataract under the microscope, starting from the day their eyes opened. Glutathione and malondialdehyde levels were evaluated in both serum and lenticular samples while protein carbonyl level was studied only in lenticular samples. RESULTS: In group 1, 50% of the rats developed dense nuclear opacities and 50% developed slight nuclear opacities, while in group 2 only 14.3% developed dense nuclear opacities and 21.4% developed slight nuclear opacities (p < 0.05). None of the rats in group 3 developed any lens opacity. In lenticular samples, mean glutathione level was statistically lower in group 1 compared to groups 2 and 3 (p < 0.05), while malondialdehyde and protein carbonyl levels were both statistically higher in group 1 compared to groups 2 and 3 (p < 0.05). Serum level of glutathione was statistically lower in group 1 compared to groups 2 and 3 (p < 0.05), while serum malondialdehyde level was statistically lower in group 3 compared to groups 1 and 2. CONCLUSIONS: N-acetylcysteine appears to inhibit selenite-induced cataractogenesis in the rat model, and this seems to be caused by the prevention of oxidative damage.

Dyspepsia in Turkish patients on continuous ambulatory peritoneal dialysis.

BACKGROUND AND AIMS: Although dyspepsia is very common in uremic patients, there is not much data on the prevalence of dyspepsia undergoing continuous ambulatory peritoneal dialysis (CAPD). The aims of this study are to assess the prevalence of dyspepsia, Helicobacter pylori, and the association between dyspeptic symptoms and diabetes. METHODS: One hundred and thirty CAPD patients were included in the study. The presence or absence of dyspepsia was assessed by using the Hong Kong Index of Dyspepsia (HKID) Questionnaire. A score of >or=16 indicates the presence of dyspepsia. The patients who were diagnosed with dyspepsia had endoscopic examination and were judged to be infected with H. pylori if the organism was demonstrated in the biopsy. RESULTS: Sixty-four of 130 CAPD patients (49.2%) had a HKID score of 16 or more. H. pylori was identified in 17 of 64 CAPD patients with dyspepsia (26.6%). Thirty-four patients (25.8%) were diabetic, and there was no association between diabetes and dyspepsia (P=0.68). The most frequent finding in patients with dyspepsia was gastritis or gastric ulcer in endoscopic evaluation. The mean serum albumin level was also not statistically significantly different between the two groups. CONCLUSIONS: Dyspepsia is common and the prevalence of H. pylori infection is 26.6% in our CAPD patients with dyspepsia. Dyspepsia is not associated with the presence of H. pylori and diabetes in CAPD patients. Large-scale studies are needed to elucidate dyspepsia related risk factors and physiopathological mechanisms.

Relation between serum thyroid hormone and 'nondipper' circadian blood pressure variability.

Currently, the pathogenesis of nondipper hypertension remains largely unclear in patients without any renal or endocrine pathology. It is well known that overt hypothyroidism is strongly associated with diastolic hypertension. However, no study has addressed the pathogenic role of TSH, free T3 (FT3), and free T4 (FT4) in nondipper hypertension. The aim of the present investigation is to evaluate if higher TSH, low FT3 and FT4 would be associated with a nondipper hypertension profile, in patients with normal renal function and without any overt thyroid hormone disorder. 131 subjects were screened and those who met the following inclusion criteria were enrolled: (1) glomerular filtration rate (GFR) >60 ml/min; (2) no history of thyroid disorders; (3) no history of thyroid hormone medication. All subjects underwent 24-hour ambulatory blood pressure monitoring on a usual working day. Of the total population, 59 patients (45%) were classified as dippers and 72 (55%) were classified as nondippers. The only significant differences between dipper and nondipper patients appear to be related to FT3 levels and GFR. Nondipper patients had lower FT3 levels (4.5 +/- 0.6 vs. 4.0 +/- 0.9 pmol/l, p = 0.02) and low GFR (80.5 +/- 12.2 vs. 86.9 +/- 16.9 ml/min, p = 0.03), compared to dipper patients. The final regression model included serum TSH, FT3 levels, and GFR; the only independent predictor of nondipper hypertension was FT3 (p = 0.04). In conclusion, even if the mechanisms of our findings remain incompletely understood, we demonstrate a graded independent relation between lower level of FT3 and the risk of nondipping. Further studies are warranted to confirm this relationship and to elucidate the pathogenetic mechanisms of this relationship.

Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions.

BACKGROUND: Hyperuricemia has been associated with the development of hypertension, cardiovascular, and renal disease. However, there is no data about the effect of lowering uric acid level on hypertension, renal function, and proteinuria in patients with glomerular filtration rate (GFR) >60 ml/min. We therefore conducted a prospective study to investigate the benefits of allopurinol treatment in hyperuricemic patients with normal renal function. MATERIALS AND METHODS: Forty-eight hyperuricemic and 21 normouricemic patients were included in the study. Hyperuricemic patients received 300 mg/day allopurinol for three months. All patients' serum creatinine level, 24-h urine protein level, glomerular filtration rate, and blood pressure levels were measured at baseline and after three months of treatment. RESULTS: A total of 59 patients completed the three-month follow-up period of observation. In the allopurinol group, serum uric acid levels, GFR, systolic and diastolic blood pressure, and C-reactive protein (CRP) levels significantly improved (P < 0.05). However, urine protein excretion remained unchanged (P > 0.05). No correlation was observed between changes in GFR and changes in CRP, or blood pressure in the allopurinol group. No significant changes were observed in the control group (P > 0.05). CONCLUSION: We bring indirect evidence that hyperuricemia increases blood pressure, and decreases GFR. Hence, management of hyperuricemia may prevent the progression of renal disease, even in patients with normal renal function, suggesting that early treatment with allopurinol should be an important part of the management of chronic kidney disease (CKD) patients. Long-term follow-up studies are warranted to identify the benefits of uric acid management on renal function and hypertension.

Relation between serum calcium, phosphate, parathyroid hormone and 'nondipper' circadian blood pressure variability profile in patients with normal renal function.

BACKGROUND AND AIMS: In patients with renal disease, an association between abnormal circadian blood pressure profile and abnormalities in bone and mineral metabolism, including vascular calcifications, is well known. However, such a link has not yet been reported in hypertensive patients with normal renal function. We aimed to evaluate if higher serum phosphate, calcium, parathyroid hormone (PTH) level and the calcium x phosphate (Ca x P) product would be associated with a nondipper hypertension, in patients with normal renal function and without any PTH disorder. METHODS: 190 hypertensive subjects with the following inclusion criteria were enrolled: (1) normal phosphate and PTH levels; (2) glomerular filtration rate (GFR) >60 ml/min, and (3) no history of calcium, phosphate, vitamin D medication and hyperparathyroidism. RESULTS: Of the total population, 76 patients (40%) were classified as dippers and 114 (60%) as nondippers. Nondipper patients had higher levels of phosphate (3.70 +/- 0.61 vs. 3.35 +/- 0.44 mg/dl, p = 0.001), Ca x P product (35.4 +/- 6.5 vs. 31.5 +/- 5.0, p = 0.001) and PTH (75.7 +/- 28.8 vs. 46.6 +/- 17.1 pg/ml, p = 0.000) compared to dipper patients. Independent predictors (multiple regression) for nondipper hypertension were PTH (beta = 0.43, p = 0.001) and phosphate (beta = 0.9, p = 0.03). CONCLUSION: We demonstrate a graded independent relation between higher levels of phosphate, PTH, Ca x P product and the risk of nondipping in hypertensive patients with an estimated GFR of >60 ml/min and normal mineral metabolism.

Comparison of effects of darbepoetin alfa and epoetin alfa on serum endothelin level and blood pressure.

It is well known that epoetin alfa increases serum endothelin (ET)-1 and blood pressure. No data are available, however, on the effects of darbepoetin alfa on serum ET-1 and blood pressure. This study was conducted to compare the effects of darbepoetin alfa and epoetin alfa on serum ET-1 and blood pressure in patients on hemodialysis (HD). A total of 42 patients on HD were included in the study. Serum samples for measuring levels of ET-1 were taken 30 min after administration of epoetin alfa. After blood samples had been taken from all patients, epoetin alfa was changed to darbepoetin alfa. Three months after the start of darbepoetin alfa treatment, blood samples were taken to measure the same parameters. Mean arterial blood pressure was measured before recombinant human erythropoietin (EPO) administration and 30 min after EPO administration while patients were taking epoetin alfa or darbepoetin alfa. Injection of epoetin alfa or darbepoetin alfa significantly increased serum ET-1 levels compared with levels in those patients who were not on EPO therapy (P<.05). When the effects of epoetin alfa on serum ET-1 level were compared with those of darbepoetin alfa, the 2 types of EPO were found to increase serum ET-1 levels similarly (P>.05). Administration of epoetin alfa or darbepoetin alfa increased systolic and diastolic blood pressures significantly over values in the control group (P<.05). Serum systolic and diastolic blood pressures increased similarly after injection of epoetin alfa or darbepoetin alfa. Administration of darbepoetin alfa increased blood pressure in patients on HD in a way that was positively correlated with enhanced ET-1 release; a similar correlation was noted with epoetin alfa.

Nitric oxide affects serum ferritin levels in children with iron deficiency.

In iron deficiency, serum levels of ferritin decrease. The lack of iron has been thought to be the main factor in this decrease, but another potential factor is nitric oxide, which has been shown to affect ferritin metabolism in vitro. The aim of this study was therefore to evaluate in children with iron deficiency the relation of serum ferritin, nitric oxide degradation products (nitrate and nitrite), and endothelin-1, a protein closely related to nitric oxide function. A total of 80 children were included in the study (39 with iron deficiency, 41 controls). Serum levels of ferritin, nitrate, nitrite, and endothelin-1 were measured in all participants. In children with iron deficiency, nitrate and nitrite levels were significantly higher (p < .009 and .01, respectively). Also, serum ferritin was negatively correlated with serum levels of nitrate and nitrite (p = .034, r = -.254 for nitrate and p = .01, r = -.593 for nitrite). No statistical relationship was found between serum ferritin and endothelin-1.

Effects of zileuton on the development of autoimmune myocarditis in an experimental rat model.

BACKGROUND: Myocarditis is associated with high morbidity and mortality in childhood, but the pathogenesis of this disease is still unclear. Current knowledge indicates that complex immunopathogenic mechanisms are involved. It is understood that leukotrienes play an important role in the inflammation associated with asthma, and recent reports indicate that leukotrienes participate in immune processes and in autoimmunity. OBJECTIVE: The aim of this study was to assess the role of leukotriene synthesis in the development of myocardial inflammation and necrosis during myocarditis. METHODS: The effect of zileuton, a leukotriene synthesis inhibitor, was assessed in an experimental model of autoimmune myocarditis in rats. Healthy adult (10-week-old) male Wistar albino rats were randomly divided into 3 groups. Groups A and B received injections of 1.0 mg porcine cardiac myosin to induce autoimmune myocarditis and group C (the control group) received phosphate-buffered saline. Group B also received zileuton by oral gavage at 100 mg/kg · d(-1). Myocardial inflammation was assessed biochemically via serum concentrations of creatine kinase MB subunit (CK-MB) and troponin T. Cardiac tissue was assessed macroscopically (0 = no inflammation; 1 = a small discolored focus; 2 = diffuse discolored areas covering less than half of the cardiac surface; 3 = diffuse discolored areas covering more than half of the cardiac surface) and microscopically (0 = no inflammation; 1 = ⪯5% infiltration; 2 = 5% to <10% infiltration; 3 = 10% to < 20% infiltration; 4 = >20% infiltration). RESULTS: Twenty-four rats were divided equally into 3 groups. All rats survived the duration of the study. After 21 days, all rats were euthanized. No significant differences were found between groups A and B in terms of serum concentrations of CK-MB or troponin T. The microscopic pathology score was significantly lower in group B (myosin + zileuton) than in group A (myosin only) (0.12 [0.35] vs 1.25 [1.03]; P = 0.023). The microscopic pathology score was significantly higher in group A than in group C (1.25 [1.03] vs 0; P < 0.01), but the difference between groups B and C was not statistically significant. The macroscopic pathology score was significantly higher in group A than in group B (1.37 [0.91] vs 0.37 [0.51]; P = 0.029). The macroscopic pathology score was significantly higher in group A than in group C (1.37 [0.91] vs 0; P < 0.01). There was no significant difference in macroscopic scores between groups B and C (0.37 [0.51] vs 0). CONCLUSIONS: In this study of the effects of zileuton in an experimental rat model of autoimmune myocarditis, no significant differences were found in the serum concentrations of the biochemical markers in the 2 groups administered myosin. However, lower macroscopic and microscopic inflammation scores in the zileuton-treated group (group B) compared with the group administered only myosin (group A) suggest that zileuton, a leukotriene-synthesis inhibitor, may suppress the development of experimental autoimmune myocarditis in rats.

Oxidative stress and protein oxidation in pseudoexfoliation syndrome.

PURPOSE: To investigate the oxidant/antioxidant status and protein oxidation in pseudoexfoliation syndrome. METHODS: The activity of serum superoxide dismutase (SOD) and the levels of serum malondialdehyde (MDA) and protein carbonyl (PC) were measured in 50 patients with pseudoexfoliation (PEX) and in 55 healthy controls. RESULTS: There was significant difference in the SOD activity in PEX group compared with the control group (p < 0.001). In addition, MDA and PC levels were significantly higher in patients than in the controls (p < 0.001). CONCLUSIONS: Decrease in SOD activity and the higher levels of MDA and PC indicate increased oxidative stress. Our results suggest a possible role of oxidative stress in pathology of PEX syndrome.

Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins.

AIM: Dyslipidemia is common among patients with end-stage renal disease, whether treated by hemodialysis (HD) or peritoneal dialysis (PD). However, there are not enough data about the effect of dialysis type on serum lipoprotein (a) [Lp(a)], apolipoprotein (a) [Apo(a)], apolipoprotein (b) [Apo(b)], and lipid levels. The aim of this study was to determine the effect of dialysis type on serum lipid levels. MATERIALS AND METHODS: This study enrolled 40 HD patients (20 men and 20 women, aged 48.1 +/- 17.6 years) and 69 PD patients (35 men and 34 women, aged 45.2 +/- 16.3 years). Serum lipid profile including total cholesterol (TC), low-density lipoprotein (LDL-C), high-density lipoprotein (HDL-C), triglyceride (TG), Apo(a), Apo(b), and Lp(a) were determined in HD and PD patients. Patients who have used statins within the last six months were not included in the study. RESULTS: No significant differences in TC, LDL-C, HDL-C, TG, Apo(a), Apo(b), or Lp(a) serum levels were found between HD and PD patients. Serum TC, LDL-C, HDL-C, TG, Apo(a), Apo(b), and Lp(a) in HD and PD patients were 172.2 +/- 42.7 (mg/dL) vs. 181.0 +/- 53.0 (mg/dL), 97.2 +/- 36.2 (mg/dL) vs. 101.4 +/- 33.6 (mg/dL), 45.3 +/- 11.9 (mg/dL) vs. 41.4 +/- 11.1 (mg/dL), 144.7 +/- 71.8 (mg/dL) vs. 173.0 +/- 76.8 (mg/dL), 1.2 +/- 0.5 (g/L) vs. 1.0 +/- 0.2 (g/L), 0.9 +/- 0.3 (g/L) vs. 1.2 +/- 0.3 (g/L), and 43.1 +/- 40.6 (mg/dL) vs. 46.0 +/- 42.7 (mg/dL), respectively. CONCLUSION: The results of this study show that the maintenance CAPD treatment is associated with more pronounced alterations of the lipoproteins and lipid metabolism than those observed during HD treatment.

Use of melatonin to prevent selenite-induced cataract formation in rat eyes.

PURPOSE: To evaluate effects of melatonin on sodium selenite-induced cataract formation. METHODS: Twenty-three Sprague-Dawley rat pups were randomized into three groups. Group 1(n = 9), injected with selenite (s.c.) on postpartum day 10; group 2 (n = 7), injected with selenite (s.c.) on day 10 plus melatonin (i.p.) on days 8-15; group 3 (n = 7), saline-injected controls. Development of cataract was assessed weekly under a dissection microscope. Rat lenses and serums were analyzed for antioxidant enzymes superoxide dismutase (SOD) and catalase (CAT); oxidative stress indicators xanthine oxidase (XO) and malondialdehyde (MDA), a marker of lipid peroxidation; and protein carbonyl (PC), a marker of protein oxidation. RESULTS: Significant differences (p < 0.05) were seen in cataract development by the three groups. All rats developed dense nuclear cataract in group 1. Dense nuclear cataract was not observed in group 2: five of seven rats developed minor cataracts, while the other two had clear lenses. In control rats (group 3), all lenses remained clear. In selenite group (group 1), lens and serum levels of MDA, PC, and XO were significantly higher and levels of SOD and CAT were significantly lower than those in control group (p < 0.001). In selenite+melatonin group (group 2), lens and serum levels of MDA, PC, and XO significantly decreased and levels of SOD and CAT significantly increased when compared with selenite group. CONCLUSIONS: Studies with the rat selenite cataract model strongly support the activity of melatonin as an endogenous antioxidant and anticataract agent.